PLANO, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) announced today that it plans to release financial and operational results for first quarter 2025 at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, April 24, 2025. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call.
Conference call details:
An audio replay will be available for seven days and can be accessed by dialing (800) 770-2030 or (609) 800-9909 and using Conference ID 3120125. The conference call will also be available live or via archived replay on the Investor Relations section of the Integer website at: investor.integer.net.
From time to time, Integer posts information that may be of interest to investors on its website at investor.integer.net. To automatically receive Integer financial news by email, please visit investor.integer.net and subscribe to email alerts.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: Kristen Stewart This email address is being protected from spambots. You need JavaScript enabled to view it. 551.337.3973 | Media Relations: Kelly Butler This email address is being protected from spambots. You need JavaScript enabled to view it. 469.731.6617 |
| Last Trade: | US$68.00 |
| Daily Change: | -2.20 -3.13 |
| Daily Volume: | 2,107,394 |
| Market Cap: | US$2.380B |
October 24, 2025 October 23, 2025 July 24, 2025 July 10, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
